上海交大赵大海教授接受央视专访：新型新冠疫苗的上市与疫苗的国际合作
上海交通大学国际与公共事务学院教授、博士生导师，上海交通大学-耶鲁大学卫生政策联合研究中心执行主任赵大海，自新冠肺炎疫情暴发以来，对于新冠疫情暴发、防控以及卫生政策第56次接受中央电视台的直播专访，也是第90次接受央视、上视专访。2021年5月13日，赵大海在中央电视台英语频道《中国24小时》节目，就在中国新上市的新型新冠疫苗以及疫苗的国际合作等相关话题进行了解释。现将有关访谈内容翻译并摘录如下。
主持人：正如专家(中国疾病预防控制中心主任高福)所提到的，这种新型疫苗(三针免疫程序的重组亚单位疫苗)不仅更安全而且更有效。您的观察结果是什么？我们可以把它作为突破还是另一种选择？
赵大海：新型的新冠疫苗(智克威得)，是人们接种新冠疫苗的重要补充和另一种选择。由于无论在中国还是在全球，新冠疫苗需求量远远大于目前的供应量。这种以易大批量生产、储存和运输要求较低为特征的重组亚单位新冠疫苗，确实是一个很好的新冠疫苗接种的补充。此外，在这种新型新冠疫苗的安全性和有效性方面，已得到了国家药品监督管理局的完全认可。与此同时，实际上在市场上的每种新冠疫苗的安全性和有效性都是得到充分保障的。公众没有必要为此担心。此外，我相信在近期将会有更多种类或厂家的新冠疫苗获得批准上市，这对于尽快满足公众对新冠疫苗接种的需求是极为有利的。
主持人： 中国科学家认为中国应该欢迎外国疫苗进入中国市场。在新冠疫苗合作方面，世界还能做些什么？
赵大海：鉴于疫苗是对抗新冠全球大流行的最重要武器，新冠疫苗的国际合作对所有国家而言都是非常有必要的。除了目前的新冠肺炎疫苗实施计划(COVAX)，疫苗的国际合作任重而道远。首先，发展中国家和发达国家在新冠疫苗的分配上是严重不公平的。经济发展落后国家获得的新冠疫苗远远少于发达国家。因此，发达国家应有义务为经济发展落后国家分配更多的新冠疫苗。其次，各国新冠疫苗的研发和生产公司需要更多的合作。鉴于当前新冠在全球的大流行，关于疫苗研发和生产的知识和技术交流对整个人类而言都是极为重要的。
供稿者：国务学院
日期：2021年5月14日
Dahai ZHAO’s Exclusive Interview with CGTN: Marketing recommendations for coronavirus vaccine and international cooperation
Dahai Zhao, a doctoral supervisor at the School of International and Public Affairs of Shanghai Jiao Tong University and Executive Director of Shanghai Jiao Tong University-Yale University Joint Research Center for Health Policy, has been interviewed by CGYN for the 56st time (the 90st time by CGTN / ShanghaiTV) since the COVID-19 pandemic. On May 13, 2021, Zhao commented on the newly marketed coronavirus vaccine in China and international cooperation on vaccines on “China 24” of CGTN.
Anchor: As the expert mentioned, this new type of vaccine is expected to be not only safer but also more effective. What's your observation? Can we take it as a breakthrough or another choice?
ZHAO: The new type of COVID-19 vaccine is an important supplement and another choice for people’s vaccinating. Due to the fact that the COVID-19 vaccine demand is much more than the current supply, either in China or the whole world. This type of COVID-19 vaccine which is good at mass production, simple storage and transportation, is really a good supplement for the current COVID-19 vaccine supply. Furthermore, in terms of the safety and effectiveness of this new type of vaccine, it has been fully confirmed by the Chinese National Medical Products Administration. Further, the safety and effectiveness of each type of vaccine of COVID-19 on the market is fully confirmed. It is not necessary for citizens to worry about this. In addition, I believe more COVID-19 vaccines from China will be approved in the near future. The demand for the COVID-19 vaccine will be met as soon as possible.
Anchor: Chinese scientists believe China should welcome foreign vaccines. What more can the world do in terms of vaccine cooperation?
ZHAO: Considering the vaccine is the most important weapon to combat the COVID-19 pandemic, the vaccine cooperation is necessary for all countries. Besides of the current COVAX, the vaccine cooperation should be done much more. First, the current distribution on vaccines is not fair between developing and developed countries. The poor countries have obtained much less vaccines than developed countries. Therefore, developed countries should have an obligation to allocate more vaccines for poor countries. Second, the research and production companies on COVID-19 vaccines in different countries need much more cooperation. Considering the pandemic of COVID-19 in the world, knowledge and technology exchange on the vaccine research and production is necessary for the whole human being.
Contributor: SIPA, SJTU
Date: May 5, 2021